Current standard of care for T1DM requires routine blood glucose monitoring and exogenous insulin administration, a nonphysiologic treatment resulting in the development of secondary complications and, consequently, reduced quality-of-life and increased burden of disease (30, 31, 35–46). This evidence concerns the gene INS and type 1 diabetes mellitus.